Programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies

Last revised by Yuranga Weerakkody on 26 Apr 2020

Programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies interact with a protein called PD-1 on T-cells and can be useful in determining if certain immunomodulation therapies can be used in treatment of certain types of cancers. PD-L1 is a major immune checkpoint protein that mediates antitumor immune suppression and response. 

Imaging applications

Nuclear medicine

Some studies show that agents, such as the peptide-based imaging agent, gallium-68-WL12 can be used to detect PD-L1 expression in tumors non-invasively by positron emission tomography (PET) 5

See also


ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.